4 results about "Aceclofenac" patented technology

The present application provides a kind of aceclofenac enteric microcapsule and its preparation method, the microcapsule includes core and coating, the core includes pill core, aceclofenac, adhesive;The coating includes enteric coating material, plasticizer, anti-adhesive. By screening and optimizing the type and proportion of adhesive and enteric material, optimizing and controlling the preparation process parameters, effectively improve the stability and long-term stability of aceclofenac sustained-release microcapsule, block the release of drug in mouth and stomach, direct the drug to small intestine and slowly release, and the release effect is long-acting and durable.

Embodiments herein provide a pharmaceutical formulation comprising an anti-inflammatory antipyretic agent with reduced side effects, addressing gastric problems. An enteric-coated tablet of the present invention comprises esomeprazole, aceclofenac, and paracetamol, along with maize starch, microcrystalline cellulose, povidone K30, colloidal anhydrous silica, and magnesium stearate.

The invention relates to the technical field of pharmaceutical preparations, and discloses an aceclofenac enteric capsule and application thereof in rheumatoid arthritis, and the aceclofenac enteric capsule composition comprises the following components in parts by weight: aceclofenac, choline-aspartate ionic liquid, sodium alginate, low methoxyl pectin and micronized calcium carbonate. The invention aims to solve the technical problems that aceclofenac is poor in solubility and a conventional enteric-coated preparation has a burst release effect. According to the composition, a pH-sensitive in-situ gel drug delivery system is constructed; when the content of the composition is in a gastric acid environment, micronized calcium carbonate is activated and calcium ions are released in situ; and after entering the neutral environment of the intestinal tract, the calcium ions are crosslinked with the sodium alginate and the low-methoxyl pectin, so that the liquid content is quickly converted into semi-solid gel with biological adhesiveness. The system realizes the positioning retention and long-acting slow release of the medicine in the intestinal tract, effectively avoids the violent fluctuation of the blood concentration, and is expected to improve the bioavailability of the medicine.

The present invention provides aceclofenac, amlodipine or doxazosin, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment or prophylaxis of Attention Deficit / Hyperactivity Disorder (ADHD). The invention also provides kits and methods for the treatment or prophylaxis of ADHD.